Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Correction: A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). Local targets link to admitted publications; unresolved targets remain external evidence.
A phase II study of docetaxel and pembrolizumab plus interleukin 12 gene therapy in nonmetastatic, anthracycline-refractory triple-negative breast cancer (INTEGRAL)
10.1158/1078-0432.ccr-25-2649 · 2026 · External reference
